Amar Kishan
3,481 posts
user avatar
Amar Kishan
@AmarUKishan
Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA. All views are my own.
uclahealth.org/amar-kishan
Joined November 2017
812
Following
4,407
Followers
  • Pinned
    user avatar
    Amar Kishan
    @AmarUKishan
    Jun 12, 2024
    Thank you @MSteinbergMD @dgsomucla @UCLAJCCC !
    user avatar
    Michael Steinberg MD
    @MSteinbergMD
    Jun 11, 2024
    It’s a pleasure to announce the appointment of Dr. @AmarUKishan to Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center.
    Image
    13K
  • user avatar
    Amar Kishan
    @AmarUKishan
    Sep 19, 2023
    Proud to share that I have been promoted to Professor! An achievement made possible only by working with exceptional colleagues, residents, and students at an exceptional place! @MSteinbergMD @UCLAJCCC @Ucla
    39K
  • user avatar
    Amar Kishan
    @AmarUKishan
    Jan 12, 2023
    Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology jamanetwork.com/journals/jamao… (1/n)
    Image
    MRI-Guided vs CT-Guided Stereotactic Body Radiotherapy for Patients With Prostate Cancer
    From jamanetwork.com
    54K
  • user avatar
    Amar Kishan
    @AmarUKishan
    Dec 11, 2020
    Pleased to share the results of our "MASTER" systematic review and meta-analysis of local salvage therapies for radioreccurent PCa @EUPlatinum europeanurology.com/article/S0302-…
  • user avatar
    Amar Kishan
    @AmarUKishan
    Feb 15, 2022
    bit.ly/33kuBmA Interim results of the MIRAGE randomized trial of MRI-guided vs. CT-guided SBRT to be presented at #GU22 @ASCO, suggesting significantly reduced acute GU≥2 and GI≥2 toxicity with MRI-guidance. @UCLAJCCC
  • user avatar
    Amar Kishan
    @AmarUKishan
    Feb 23, 2023
    Detailed topographic analysis of PSMA-defined recurrences after RP in 226 men suggests a majority of recurrences occur inferiorly and posteriorly. Potentially major implications for post-operative RT contouring.
    user avatar
    JNM
    @JournalofNucMed
    Feb 22, 2023
    Detailed PSMA PET mapping of prostatic bed recurrence patterns provides important information for a redefinition of radiotherapy contouring guidelines. ow.ly/1sGw50MZ4c2 #NuclearMedicine #ProstateCancer @AmarUKishan @a_dalpra @CalaisJeremie @MinsongUC @Matthias_R_Benz
    Image
    29K
  • user avatar
    Amar Kishan
    @AmarUKishan
    Oct 21, 2022
    Very pleased to present the 4th MARCAP analysis, "SANDSTORM" now live online at ascopubs.org/doi/full/10.12… @JCO_ASCO (1/n)
    ascopubs.org
    Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic...
    PURPOSEThe sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of...
  • user avatar
    Amar Kishan
    @AmarUKishan
    Feb 17, 2022
    Interim results of the MIRAGE trial at @ASCO GU now! See a brief summary below. Join me for a live Q&A using #MIRAGEQA at 1 pm PST/4 PM EST!
    Image
    00:00
  • user avatar
    Amar Kishan
    @AmarUKishan
    Sep 15, 2021
    Very proud to receive this award from @dgsomucla! Kind thanks to my patients, medical students, residents, and colleagues at @UCLAJCCC
    user avatar
    Michael Steinberg MD
    @MSteinbergMD
    Sep 15, 2021
    Proud to share that our #uclaradonc Dr. @AmarUKishan is the 2021 recipient of the prestigious Leonard Tow Humanism in Medicine Award. The award recognizes faculty members who demonstrate clinical excellence & outstanding compassion in the delivery of care.
    Image
  • user avatar
    Amar Kishan
    @AmarUKishan
    Sep 9, 2022
    Very pleased to announce that the LUNAR trial is now open @UCLAJCCC clinicaltrials.gov/ct2/show/NCT05…. SBRT alone vs. 177Lu-PSMA x 2 + SBRT for oligorecurrent hormone-sensitive prostate cancer!

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms of Service|Privacy Policy|Cookie Policy|Accessibility|Ads info|© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
Advertisement
Advertisement